Prevalence and Detection Rate of Underlying Disease in Men with Erectile Dysfunction Receiving Phosphodiesterase Type 5 Inhibitors in the United Kingdom: A Retrospective Database Study

M.G. Kirby, G. Schnetzler, K.H. Zhou, and T. Symonds

Morales, Antonio Martin MD, FECSM
Bondil, Pierre MD
Morley, John E. MB, BCh

^*Instituto de Urologia Malaga, Málaga, Spain; ^†General Hospital, Chambery, France; ^‡Saint Louis University School of Medicine, St. Louis, MO, USA

The Journal of Sexual Medicine 11:p 127-130, March 2014.

“Prevalence and Detection Rate of Underlying Disease in Men with Erectile Dysfunction Receiving Phosphodiesterase Type 5 Inhibitors in the United Kingdom: A Retrospective Database Study” was published in the International Journal of Clinical Practice in 2011. The following are comments regarding this publication discussing its relevance at the time of publication as well as in 2013. This commentary is part of a supplement that was sponsored by Pfizer; however, the content was developed by the authors, and the views expressed are solely those of the authors.